When the National Cancer Institute (NCI) removed all prostate-specific antigen (PSA) data from the Surveillance, Epidemiology, and End Results (SEER) and SEER-Medicare programs, it rendered many of ...
In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine ...
Analysis of the first subset of linked SEER patient data demonstrates DecisionDx®-Melanoma testing was associated with improved overall survival rates compared to untested patients DecisionDx-Melanoma ...
NCI recently announced that it had removed all PSA data from the SEER and SEER-Medicare programs. The data were removed after quality control checks revealed that a substantial number of PSA values ...
Large data sets like SEER need better quality control checks and researchers and clinicians who use these data sets should also consider using secondary data analyses that answer specific research ...
IN THIS issue of the Journal of Clinical Oncology, Anderson et al 1 analyze data from the Surveillance, Epidemiology, and End-Results (SEER) Program to determine whether inflammatory breast cancer ...
SOUTH SAN FRANCISCO, Calif., April 21, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate ...
SOUTH SAN FRANCISCO – Veracyte, Inc. (NASDAQ: VCYT), a global cancer diagnostics company valued at $2.38 billion with impressive revenue growth of 23.46% over the last twelve months, announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback